Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study

AstraZeneca171 enrolled

Overview

The purpose of this study is to evaluate the incidence rate of progression of disease, to describe the diagnostic and clinical management in patients with Metastatic Breast Cancer in the clinical practice in Bulgaria.

A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria

Study Type

OBSERVATIONAL

Enrollment

171

Conditions

Metastatic Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * New diagnosis of breast cancer according to ICD-10 with confirmed metastasis * Confirmed diagnosis between 1st July 2010 and 30th June 2011. * Female patient managed for her disease at the same setting where final diagnosis of MBC was performed. Exclusion Criteria: * History of concurrent or other primary malignancies (except curatively resected non-melanoma skin cancer or in situ cervical cancer).

Locations (6)

Research Site

Pleven, Bulgaria

Research Site

Plovdiv, Bulgaria

Research Site

Rousse, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Stara Zagora, Bulgaria

Outcomes

Primary Outcomes

Number of progression events on a per patient-year-basis

Time frame: Up to 2 years 5 months

Secondary Outcomes

Proportion of patients among study population who have not progressed at 12 and 18 months after they were diagnosed

Time frame: Up to 2 years 5 months

Median and mean time interval that elapsed between diagnosis and first objective tumor progression (TTP) event and subsequent events

Time frame: Up to 2 years 5 months

Median and mean time from the date of diagnosis to the date of breast cancer progression or death whichever occurred first

Time frame: Up to 2 years 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.